Abstract

Worldwide epidemiological data reveal extremely high prevalence of anxiety and depressive disorders, leading to loss of fitness for work and the associated increased economic burden on society. In this regard, it seems crucial to improve the efficacy of standard psychopharmacological treatment of anxiety and depression. The relevance of the study is determined by the identification of combined immune-metabolic disorders in mixed anxiety and depressive disorder.Laboratory and clinical parameters of patients with mixed anxiety-depressive disorder were assessed. It was found that symptoms of anxiety and depression were accompanied by changes in immune and metabolic status. Statistically significant correlations between symptoms of anxiety and depression, and immune-metabolic statuses were identified,which indicates the possible existence of immune-oxidative stress in patients with symptoms of anxiety and depression, and damage to all parts of the immune system: humoral, phagocytic, cytokine, free-radical oxidation, and antioxidant system dependent immunity. These findings indicate the need to take into account changes in immune and metabolic status in patients with mixed anxiety and depressive disorder and consider the possibility of adding immunocorrective drugs to the treatment regimen in order to increase the effectiveness of standard psychopharmacological therapy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.